Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90, Durvalumab, Tremelimumab, and Zanzalintinib in Unresectable and Locally-Advanced Hepatocellular Carcinoma
NCT07511504Phase 2Not yet recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib, durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by OHSU Knight Cancer Institute. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
zanzalintinibdurvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07511504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511504.